万邦医药
(301520)
| 流通市值：23.57亿 | | | 总市值：67.16亿 |
| 流通股本：3269.84万 | | | 总股本：9317.14万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 214,335,975.9 | 57,996,749.28 | 150,297,730.04 | 60,946,286.7 |
| 结算备付金 | - | - | 0 | 0 |
| 拆出资金 | - | - | 0 | 0 |
| 交易性金融资产 | 853,839,628.29 | 1,082,718,946.68 | 1,000,718,794.89 | 1,100,794,578.3 |
| 衍生金融资产 | - | - | 0 | 0 |
| 应收票据及应收账款 | 97,217,311.29 | 73,627,295.06 | 84,417,948.08 | 64,548,259.07 |
| 其中：应收票据 | 1,366,474.8 | 3,844,071.8 | 3,092,900 | 4,021,768.06 |
| 应收账款 | 95,850,836.49 | 69,783,223.26 | 81,325,048.08 | 60,526,491.01 |
| 应收款项融资 | 19,804,392.64 | 0 | 240,270 | 0 |
| 预付款项 | 13,034,418.65 | 13,253,796.5 | 8,528,043.52 | 11,502,053.99 |
| 应收保费 | - | 0 | 0 | 0 |
| 应收分保账款 | - | 0 | 0 | 0 |
| 应收分保合同准备金 | - | 0 | 0 | 0 |
| 其他应收款合计 | 3,124,999.85 | 3,275,804.82 | 2,073,081.42 | 7,034,124.89 |
| 应收股利 | - | 0 | 0 | 0 |
| 买入返售金融资产 | - | 0 | 0 | 0 |
| 存货 | 1,415,210.44 | 1,322,207.01 | 871,291.85 | 963,381.38 |
| 合同资产 | 128,645,343.66 | 112,735,215.81 | 106,856,965.31 | 111,476,027.79 |
| 其他流动资产 | 5,478,467.62 | 6,130,162.2 | 6,148,328.32 | 5,905,873.69 |
| 流动资产合计 | 1,336,895,748.34 | 1,351,060,177.36 | 1,360,152,453.43 | 1,363,170,585.81 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | - | 0 | 0 | 0 |
| 其他权益工具投资 | 3,160,478 | 0 | 0 | 10,000,000 |
| 其他非流动金融资产 | 27,000,000 | 27,000,000 | 24,000,000 | 3,000,000 |
| 投资性房地产 | 6,397,875.35 | 6,495,738.56 | 6,593,601.77 | 6,691,464.98 |
| 固定资产 | 157,502,181.37 | 159,919,915.56 | 163,663,170.09 | 165,549,963.29 |
| 在建工程 | 45,756,583.54 | 44,921,682.13 | 36,973,015.01 | 28,888,304.53 |
| 生产性生物资产 | - | 0 | 0 | 0 |
| 油气资产 | - | 0 | 0 | 0 |
| 使用权资产 | 2,631,595.83 | 0 | 0 | 0 |
| 无形资产 | 32,412,430.56 | 9,711,509.26 | 9,916,192.96 | 10,849,910.73 |
| 商誉 | 201,636,717 | 0 | 0 | 0 |
| 长期待摊费用 | 313,310.26 | 952,785.64 | 849,947.02 | 2,066,287.18 |
| 递延所得税资产 | 4,492,430.78 | 80,468.26 | 31,730.55 | 529,785.66 |
| 其他非流动资产 | 526,099.59 | 769,307.9 | 346,331.39 | 412,207.28 |
| 非流动资产合计 | 481,829,702.28 | 249,851,407.31 | 242,373,988.79 | 227,987,923.65 |
| 资产总计 | 1,818,725,450.62 | 1,600,911,584.67 | 1,602,526,442.22 | 1,591,158,509.46 |
| 流动负债: | | | | |
| 短期借款 | 37,528,090.29 | - | 0 | 0 |
| 向中央银行借款 | - | - | 0 | 0 |
| 吸收存款及同业存放 | - | - | 0 | 0 |
| 拆入资金 | - | - | 0 | 0 |
| 交易性金融负债 | 0 | - | 0 | 0 |
| 衍生金融负债 | 0 | - | 0 | 0 |
| 应付票据及应付账款 | 50,118,541.6 | 28,313,512.72 | 33,419,430.09 | 32,247,801.97 |
| 其中：应付票据 | 0 | - | 0 | 0 |
| 应付账款 | 50,118,541.6 | 28,313,512.72 | 33,419,430.09 | 32,247,801.97 |
| 预收款项 | 0 | - | 0 | 0 |
| 合同负债 | 57,303,139.41 | 27,611,141.73 | 19,084,672.03 | 16,490,152.38 |
| 卖出回购金融资产款 | - | - | 0 | 0 |
| 应付手续费及佣金 | - | - | 0 | 0 |
| 应付职工薪酬 | 11,613,740.59 | 5,425,855.08 | 6,791,062.19 | 10,001,208.91 |
| 应交税费 | 4,222,767.14 | 657,640.34 | 594,104.46 | 739,132.92 |
| 其他应付款合计 | 102,996,933.65 | 2,419,510.05 | 2,214,083.63 | 2,067,713.17 |
| 其中:应付利息 | - | - | 0 | 0 |
| 应付股利 | - | - | 0 | 0 |
| 应付分保账款 | - | - | 0 | 0 |
| 保险合同准备金 | - | - | 0 | 0 |
| 代理买卖证券款 | - | - | 0 | 0 |
| 代理承销证券款 | - | - | 0 | 0 |
| 一年内到期的非流动负债 | 1,133,046.96 | - | 0 | 0 |
| 其他流动负债 | 2,824,612.84 | 1,153,356.49 | 3,335,022.19 | 818,518.85 |
| 流动负债合计 | 267,740,872.48 | 65,581,016.41 | 65,438,374.59 | 62,364,528.2 |
| 非流动负债: | | | | |
| 长期借款 | 0 | - | 0 | 0 |
| 应付债券 | 0 | - | 0 | 0 |
| 优先股 | - | - | 0 | 0 |
| 永续债 | - | - | 0 | 0 |
| 租赁负债 | 899,839.07 | - | 0 | 0 |
| 长期应付款 | 0 | - | 0 | 0 |
| 长期应付职工薪酬 | 0 | - | 0 | 0 |
| 预计负债 | 5,000,000 | 5,000,000 | 5,000,000 | 0 |
| 递延收益 | 9,001,772.78 | 9,452,365.85 | 9,902,958.92 | 10,339,167.39 |
| 递延所得税负债 | 6,964,469.44 | 5,243,819.55 | 6,788,956.08 | 5,688,721.91 |
| 其他非流动负债 | 0 | - | 0 | 0 |
| 非流动负债合计 | 21,866,081.29 | 19,696,185.4 | 21,691,915 | 16,027,889.3 |
| 负债合计 | 289,606,953.77 | 85,277,201.81 | 87,130,289.59 | 78,392,417.5 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 93,171,373 | 66,666,667 | 66,666,667 | 66,666,667 |
| 其他权益工具 | 0 | - | 0 | 0 |
| 优先股 | - | - | 0 | 0 |
| 永续债 | - | - | 0 | 0 |
| 资本公积 | 1,013,006,985.26 | 1,039,115,331.01 | 1,038,615,318.62 | 1,039,309,092.4 |
| 减:库存股 | 15,233,438 | 15,233,438 | 15,233,438 | 15,233,438 |
| 其他综合收益 | 0 | - | 0 | 0 |
| 专项储备 | 0 | - | 0 | 0 |
| 盈余公积 | 40,526,803.38 | 40,526,803.38 | 40,526,803.38 | 40,526,803.38 |
| 一般风险准备 | - | - | 0 | 0 |
| 未分配利润 | 365,088,602.39 | 384,559,019.47 | 384,820,801.63 | 381,496,967.18 |
| 归属于母公司股东权益合计 | 1,496,560,326.03 | 1,515,634,382.86 | 1,515,396,152.63 | 1,512,766,091.96 |
| 少数股东权益 | 32,558,170.82 | - | 0 | 0 |
| 股东权益合计 | 1,529,118,496.85 | 1,515,634,382.86 | 1,515,396,152.63 | 1,512,766,091.96 |
| 负债和股东权益合计 | 1,818,725,450.62 | 1,600,911,584.67 | 1,602,526,442.22 | 1,591,158,509.46 |
| 公告日期 | 2026-08-29 | 2026-04-23 | 2026-04-23 | 2025-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |